Concepts (162)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gastrointestinal Microbiome | 19 | 2025 | 237 | 4.910 |
Why?
|
| Microbiota | 12 | 2025 | 129 | 3.500 |
Why?
|
| Clostridium Infections | 4 | 2025 | 49 | 1.880 |
Why?
|
| Enterobacteriaceae | 3 | 2024 | 18 | 1.720 |
Why?
|
| Anti-Bacterial Agents | 10 | 2025 | 791 | 1.690 |
Why?
|
| Dysbiosis | 6 | 2022 | 65 | 1.670 |
Why?
|
| Bacteriocins | 2 | 2024 | 21 | 1.070 |
Why?
|
| Inflammation | 3 | 2021 | 1147 | 0.900 |
Why?
|
| Asymptomatic Infections | 2 | 2025 | 29 | 0.900 |
Why?
|
| Succinic Acid | 1 | 2024 | 12 | 0.900 |
Why?
|
| Hyperplasia | 1 | 2024 | 88 | 0.880 |
Why?
|
| Models, Theoretical | 2 | 2016 | 271 | 0.810 |
Why?
|
| Microbial Consortia | 2 | 2025 | 10 | 0.800 |
Why?
|
| Resilience, Psychological | 1 | 2024 | 61 | 0.790 |
Why?
|
| Antimicrobial Cationic Peptides | 2 | 2020 | 58 | 0.760 |
Why?
|
| Fecal Microbiota Transplantation | 4 | 2025 | 20 | 0.720 |
Why?
|
| Escherichia coli Infections | 1 | 2022 | 87 | 0.690 |
Why?
|
| Tuberculosis | 2 | 2021 | 296 | 0.640 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2020 | 58 | 0.610 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2018 | 212 | 0.610 |
Why?
|
| Firmicutes | 1 | 2018 | 5 | 0.570 |
Why?
|
| Microbial Interactions | 1 | 2017 | 4 | 0.560 |
Why?
|
| Tetrathionic Acid | 1 | 2017 | 2 | 0.550 |
Why?
|
| Antibiosis | 1 | 2017 | 4 | 0.550 |
Why?
|
| Bacterial Physiological Phenomena | 1 | 2017 | 20 | 0.550 |
Why?
|
| Nursing Homes | 4 | 2022 | 672 | 0.530 |
Why?
|
| Immunity, Cellular | 1 | 2018 | 178 | 0.530 |
Why?
|
| Salmonella | 1 | 2017 | 44 | 0.530 |
Why?
|
| Probiotics | 1 | 2017 | 48 | 0.520 |
Why?
|
| Bacteria | 6 | 2025 | 306 | 0.510 |
Why?
|
| Genetic Engineering | 1 | 2017 | 117 | 0.500 |
Why?
|
| Bacteriophages | 1 | 2017 | 62 | 0.500 |
Why?
|
| Biofilms | 1 | 2017 | 83 | 0.500 |
Why?
|
| Biota | 1 | 2014 | 3 | 0.430 |
Why?
|
| Frailty | 3 | 2022 | 130 | 0.430 |
Why?
|
| Host-Pathogen Interactions | 1 | 2016 | 262 | 0.420 |
Why?
|
| Peptides | 1 | 2017 | 574 | 0.420 |
Why?
|
| Feces | 6 | 2025 | 112 | 0.390 |
Why?
|
| Urinary Tract Infections | 2 | 2025 | 92 | 0.390 |
Why?
|
| Mice | 8 | 2024 | 10848 | 0.390 |
Why?
|
| Gastrointestinal Tract | 1 | 2014 | 183 | 0.370 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2024 | 205 | 0.360 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2024 | 92 | 0.350 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2024 | 357 | 0.290 |
Why?
|
| Humans | 25 | 2025 | 63643 | 0.290 |
Why?
|
| Antitubercular Agents | 2 | 2021 | 84 | 0.290 |
Why?
|
| Animals | 8 | 2024 | 20695 | 0.280 |
Why?
|
| Intestinal Mucosa | 4 | 2023 | 242 | 0.240 |
Why?
|
| Computer Simulation | 2 | 2018 | 479 | 0.230 |
Why?
|
| Urine | 1 | 2025 | 45 | 0.230 |
Why?
|
| Plant Diseases | 1 | 2024 | 12 | 0.230 |
Why?
|
| Immunity, Innate | 2 | 2023 | 797 | 0.220 |
Why?
|
| Gram-Negative Bacteria | 1 | 2024 | 57 | 0.220 |
Why?
|
| Budesonide | 1 | 2024 | 21 | 0.220 |
Why?
|
| Tumor Microenvironment | 1 | 2025 | 158 | 0.210 |
Why?
|
| Colitis, Ulcerative | 1 | 2024 | 75 | 0.210 |
Why?
|
| Feeding Methods | 1 | 2023 | 10 | 0.210 |
Why?
|
| Colon | 1 | 2024 | 149 | 0.200 |
Why?
|
| Algorithms | 2 | 2021 | 1005 | 0.200 |
Why?
|
| Metagenomics | 3 | 2022 | 28 | 0.190 |
Why?
|
| Plasma Cells | 1 | 2023 | 52 | 0.190 |
Why?
|
| Carbapenems | 1 | 2022 | 7 | 0.190 |
Why?
|
| Aged | 7 | 2025 | 14524 | 0.190 |
Why?
|
| Klebsiella pneumoniae | 1 | 2022 | 28 | 0.180 |
Why?
|
| Female | 13 | 2025 | 33026 | 0.180 |
Why?
|
| Male | 12 | 2025 | 30008 | 0.180 |
Why?
|
| Bacterial Load | 1 | 2021 | 28 | 0.170 |
Why?
|
| Biodiversity | 1 | 2021 | 38 | 0.170 |
Why?
|
| Cytokines | 1 | 2024 | 934 | 0.170 |
Why?
|
| Proton Pump Inhibitors | 1 | 2021 | 42 | 0.170 |
Why?
|
| Hospitals | 1 | 2023 | 394 | 0.160 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2022 | 102 | 0.160 |
Why?
|
| Mice, Knockout | 1 | 2024 | 2110 | 0.160 |
Why?
|
| Escherichia coli | 2 | 2022 | 707 | 0.160 |
Why?
|
| Cohort Studies | 3 | 2021 | 2576 | 0.150 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2023 | 398 | 0.150 |
Why?
|
| Aged, 80 and over | 4 | 2025 | 5502 | 0.150 |
Why?
|
| Listeriosis | 1 | 2019 | 30 | 0.150 |
Why?
|
| Mucosal-Associated Invariant T Cells | 1 | 2018 | 2 | 0.150 |
Why?
|
| Symbiosis | 1 | 2019 | 32 | 0.150 |
Why?
|
| Lymphocyte Activation | 2 | 2018 | 758 | 0.150 |
Why?
|
| Intraepithelial Lymphocytes | 1 | 2018 | 8 | 0.150 |
Why?
|
| Disk Diffusion Antimicrobial Tests | 1 | 2017 | 2 | 0.140 |
Why?
|
| Bacterial Infections | 1 | 2019 | 149 | 0.140 |
Why?
|
| Case-Control Studies | 1 | 2021 | 1121 | 0.140 |
Why?
|
| Gene Order | 1 | 2017 | 32 | 0.140 |
Why?
|
| Diffusion | 1 | 2017 | 82 | 0.140 |
Why?
|
| Middle Aged | 7 | 2025 | 17711 | 0.140 |
Why?
|
| Mice, Inbred C57BL | 1 | 2024 | 3398 | 0.130 |
Why?
|
| Adult | 7 | 2025 | 16902 | 0.130 |
Why?
|
| Mycobacterium tuberculosis | 2 | 2018 | 405 | 0.130 |
Why?
|
| Nutritional Status | 1 | 2017 | 98 | 0.130 |
Why?
|
| RNA, Ribosomal, 16S | 3 | 2022 | 88 | 0.130 |
Why?
|
| Plasmids | 1 | 2017 | 292 | 0.130 |
Why?
|
| Prevalence | 1 | 2021 | 1388 | 0.130 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 1667 | 0.120 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2017 | 111 | 0.120 |
Why?
|
| Adenocarcinoma | 1 | 2019 | 350 | 0.120 |
Why?
|
| Models, Biological | 1 | 2021 | 1181 | 0.120 |
Why?
|
| Skin Diseases, Bacterial | 1 | 2015 | 9 | 0.120 |
Why?
|
| Soft Tissue Infections | 1 | 2015 | 49 | 0.110 |
Why?
|
| Neoplasms | 1 | 2025 | 1371 | 0.110 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2019 | 677 | 0.110 |
Why?
|
| Gene Expression Regulation | 1 | 2021 | 1618 | 0.110 |
Why?
|
| Emergency Service, Hospital | 2 | 2025 | 1105 | 0.100 |
Why?
|
| Alzheimer Disease | 1 | 2019 | 722 | 0.090 |
Why?
|
| Healthy Volunteers | 2 | 2022 | 73 | 0.080 |
Why?
|
| Intestines | 2 | 2023 | 165 | 0.080 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2015 | 710 | 0.080 |
Why?
|
| Pilot Projects | 2 | 2024 | 1016 | 0.080 |
Why?
|
| Machine Learning | 2 | 2022 | 181 | 0.070 |
Why?
|
| Epithelial Cells | 2 | 2023 | 392 | 0.070 |
Why?
|
| Immunity, Mucosal | 2 | 2018 | 52 | 0.070 |
Why?
|
| Prospective Studies | 3 | 2019 | 3304 | 0.070 |
Why?
|
| Child | 3 | 2024 | 4541 | 0.060 |
Why?
|
| Bacteriuria | 1 | 2025 | 16 | 0.060 |
Why?
|
| Urinalysis | 1 | 2025 | 39 | 0.060 |
Why?
|
| Bile Acids and Salts | 1 | 2025 | 23 | 0.060 |
Why?
|
| Donor Selection | 1 | 2024 | 17 | 0.060 |
Why?
|
| Fluoroquinolones | 1 | 2024 | 34 | 0.050 |
Why?
|
| Recurrence | 1 | 2025 | 642 | 0.050 |
Why?
|
| Parturition | 1 | 2023 | 55 | 0.050 |
Why?
|
| Computational Biology | 1 | 2025 | 355 | 0.050 |
Why?
|
| Cholesterol, Dietary | 1 | 2023 | 29 | 0.050 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2024 | 172 | 0.050 |
Why?
|
| Biological Availability | 1 | 2023 | 200 | 0.050 |
Why?
|
| Double-Blind Method | 1 | 2024 | 738 | 0.050 |
Why?
|
| Immunoglobulin A | 1 | 2023 | 96 | 0.050 |
Why?
|
| Prebiotics | 1 | 2022 | 16 | 0.050 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2023 | 127 | 0.050 |
Why?
|
| Prognosis | 1 | 2025 | 1748 | 0.040 |
Why?
|
| Allografts | 1 | 2019 | 46 | 0.040 |
Why?
|
| Software | 1 | 2022 | 388 | 0.040 |
Why?
|
| Integrin alpha Chains | 1 | 2019 | 11 | 0.040 |
Why?
|
| Listeria monocytogenes | 1 | 2019 | 34 | 0.040 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2019 | 59 | 0.040 |
Why?
|
| Disease Resistance | 1 | 2018 | 24 | 0.040 |
Why?
|
| Respiratory Mucosa | 1 | 2018 | 54 | 0.040 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2019 | 86 | 0.040 |
Why?
|
| Infant | 1 | 2023 | 1654 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2019 | 190 | 0.040 |
Why?
|
| Diet | 1 | 2022 | 527 | 0.040 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2019 | 145 | 0.030 |
Why?
|
| Haiti | 1 | 2017 | 15 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2019 | 347 | 0.030 |
Why?
|
| Adolescent | 2 | 2018 | 6260 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2019 | 567 | 0.030 |
Why?
|
| Homeostasis | 1 | 2019 | 368 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2017 | 467 | 0.030 |
Why?
|
| Pregnancy | 1 | 2023 | 2338 | 0.030 |
Why?
|
| Dendritic Cells | 1 | 2019 | 525 | 0.030 |
Why?
|
| Dementia | 1 | 2019 | 262 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2019 | 1472 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 1260 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2019 | 1999 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2024 | 5711 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2015 | 305 | 0.020 |
Why?
|
| Sex Factors | 1 | 2015 | 979 | 0.020 |
Why?
|
| Age Factors | 1 | 2015 | 1567 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2015 | 725 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2017 | 2586 | 0.020 |
Why?
|
| Young Adult | 1 | 2018 | 4717 | 0.020 |
Why?
|